2.2 Diffuse large B-cell lymphoma (DLBCL) and CRISPR Cas9
Diffuse large B-cell lymphoma is
the most common non-Hodgkin’s lymphoma and has a high heterogeneity,
accounting for approximately 1/3 of all cases 29. The
standard first-line treatment regimen today is rituximab (R) + CHOP
(cyclophosphamide + adriamycin + vincristine + prednisone), with 5-year
survival rates of 60%-70% for patients taking first-line chemotherapy30, but more than 30% of patients will still develop
relapsed/refractory DLBCL due to resistance to targeted and
chemotherapeutic agents, resulting in poor prognosis29,30.